Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethyl Icosapentate and Physical Activity for Cancer Related Fatigue
NCT02940223Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Epadel in cancer-related fatigue (CRF) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Functional Assessment of Chronic Illness Therapy - Fatigue at 57 days. Started Mar 2017; status: terminated.
02
Drugs
Epadel
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT02940223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940223.